Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 31

Related Articles by Review for PubMed (Select 22259643)

1.

Novel Therapeutic Agents in Pediatric Sepsis: Peroxisome Proliferator Receptor γ (PPAR γ) Agonists.

Kaplan JM, Zingarelli B.

Open Inflamm J. 2011 Oct 7;4(Suppl 1-M14):120-124. No abstract available.

2.

Potential for peroxisome proliferator-activated receptor-gamma agonists in progression: beyond metabolism.

Fogo AB.

Curr Opin Nephrol Hypertens. 2008 May;17(3):282-5. doi: 10.1097/MNH.0b013e3282f9b1c0. Review.

PMID:
18408479
3.
4.

Evolution of peroxisome proliferator-activated receptor agonists.

Chang F, Jaber LA, Berlie HD, O'Connell MB.

Ann Pharmacother. 2007 Jun;41(6):973-83. Epub 2007 May 22. Review.

PMID:
17519293
6.

Peroxisome proliferator-activated receptor gamma: a novel target for cancer therapeutics?

Han S, Roman J.

Anticancer Drugs. 2007 Mar;18(3):237-44. Review.

PMID:
17264754
7.

Peroxisome proliferator-activated receptor gamma agonists for preventing recurrent stroke and other vascular events in patients with stroke or transient ischaemic attack.

Liu J, Wang LN.

Cochrane Database Syst Rev. 2014 Jan 8;1:CD010693. doi: 10.1002/14651858.CD010693.pub2. Review.

PMID:
24399670
8.

New Insights into the PPAR γ Agonists for the Treatment of Diabetic Nephropathy.

Jia Z, Sun Y, Yang G, Zhang A, Huang S, Heiney KM, Zhang Y.

PPAR Res. 2014;2014:818530. doi: 10.1155/2014/818530. Epub 2014 Jan 29. Review.

9.
10.

Balaglitazone: a second generation peroxisome proliferator-activated receptor (PPAR) gamma (γ) agonist.

Agrawal R, Jain P, Dikshit SN.

Mini Rev Med Chem. 2012 Feb;12(2):87-97. Review.

PMID:
22372600
11.

Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists.

Grommes C, Landreth GE, Heneka MT.

Lancet Oncol. 2004 Jul;5(7):419-29. Review.

PMID:
15231248
12.

Peroxisome proliferator-activated receptor-gamma in vascular biology.

Li J, Wang N.

Cardiovasc Hematol Disord Drug Targets. 2007 Jun;7(2):109-17. Review.

PMID:
17584045
13.
14.

Potential therapeutic role of peroxisome proliferator activated receptor-gamma agonists in psoriasis.

Malhotra S, Bansal D, Shafiq N, Pandhi P, Kumar B.

Expert Opin Pharmacother. 2005 Aug;6(9):1455-61. Review.

PMID:
16086634
15.

Peroxisome proliferator-activated receptor-gamma agonists for management and prevention of vascular disease in patients with and without diabetes mellitus.

Ríos-Vázquez R, Marzoa-Rivas R, Gil-Ortega I, Kaski JC.

Am J Cardiovasc Drugs. 2006;6(4):231-42. Review.

PMID:
16913824
16.

Peroxisome proliferator-activated receptor targets for the treatment of metabolic diseases.

Monsalve FA, Pyarasani RD, Delgado-Lopez F, Moore-Carrasco R.

Mediators Inflamm. 2013;2013:549627. doi: 10.1155/2013/549627. Epub 2013 May 27. Review.

17.

Peroxisome proliferator-activated receptor (PPAR)β/δ, a possible nexus of PPARα- and PPARγ-dependent molecular pathways in neurodegenerative diseases: Review and novel hypotheses.

Aleshin S, Strokin M, Sergeeva M, Reiser G.

Neurochem Int. 2013 Oct;63(4):322-30. doi: 10.1016/j.neuint.2013.06.012. Epub 2013 Jun 25. Review.

PMID:
23811400
18.
19.

The nuclear receptor peroxisome proliferator-activated receptor-γ promotes oligodendrocyte differentiation through mechanisms involving mitochondria and oscillatory Ca2+ waves.

Bernardo A, De Simone R, De Nuccio C, Visentin S, Minghetti L.

Biol Chem. 2013 Dec;394(12):1607-14. doi: 10.1515/hsz-2013-0152. Review.

PMID:
23770533
20.

Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons.

Tenenbaum A, Motro M, Fisman EZ.

Cardiovasc Diabetol. 2005 Sep 16;4:14. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk